Proficio Capital Partners LLC Purchases Shares of 54,928 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Proficio Capital Partners LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 54,928 shares of the medical equipment provider’s stock, valued at approximately $55,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Dunhill Financial LLC raised its stake in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the 3rd quarter valued at $35,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the fourth quarter worth $39,000. Finally, SRS Capital Advisors Inc. grew its holdings in shares of Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 285 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.95% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on ZBH shares. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Raymond James dropped their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

ZBH stock opened at $112.21 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market cap of $22.34 billion, a PE ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The business has a 50 day moving average of $107.18 and a 200-day moving average of $107.01. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $131.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company posted $2.20 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.